Literature DB >> 19959593

Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.

Cecilea C Clayton1, Michael R Bruchas, Michael L Lee, Charles Chavkin.   

Abstract

The effects of phosphorylation of the tyrosine residue in the highly conserved DRY motif expressed in the putative second cytoplasmic loop of the mu-opioid receptor were assessed after expression in human embryonic kidney (HEK) 293 cells. Tyrosine kinase activation by epidermal growth factor (EGF) or hydrogen peroxide treatment effectively increased phosphorylation of the tyrosine-166 in the mu-opioid receptor (MOR-Tyr166p) as measured by a novel phosphoselective antibody. We were surprised to find that the increase in MOR-Tyr166p immunoreactivity (ir) required coactivation by the opioid agonist [D-Ala(2),methyl-Phe(4),Gly(5)-ol]enkephalin (DAMGO), as demonstrated by both Western blot imaging of membrane proteins and confocal microscopy of transfected cells; MOR-Tyr166p-ir did not significantly increase after either DAMGO, EGF, or H(2)O(2) treatment alone. The increase in MOR-Tyr166p-ir was blocked by pretreatment with the opioid antagonist naloxone or the Src kinase inhibitor 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine. Consistent with these data, mutation of the tyrosine-166 to phenylalanine blocked the increased immunoreactivity, and untransfected HEK293 cells did not increase MOR-Tyr166p-ir after treatment. DAMGO increased guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTP gamma S) binding to membranes from cells expressing wild-type MOR or MOR-Y166F receptors in a dose-dependent manner. Pretreatment of the wild-type MOR-expressing cells with the combination of DAMGO and EGF completely blocked subsequent DAMGO stimulation of [(35)S]GTP gamma S binding membranes, whereas [(35)S]GTP gamma S binding to membranes from cells expressing mutated MOR(Y166F) was only partially inhibited. These results suggest that G-protein activation as measured by [(35)S]GTP gamma S binding can be regulated by DAMGO and EGF by convergent mechanisms and support the hypothesis that tyrosine phosphorylation within the DRY motif may reduce mu-opioid receptor-G-protein coupling efficiency.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19959593      PMCID: PMC2835424          DOI: 10.1124/mol.109.060558

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  39 in total

Review 1.  The [35S]GTPgammaS binding assay: approaches and applications in pharmacology.

Authors:  C Harrison; J R Traynor
Journal:  Life Sci       Date:  2003-12-12       Impact factor: 5.037

2.  Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat mu-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation.

Authors:  J Li; C Chen; P Huang; L Y Liu-Chen
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

3.  Cloning and pharmacological characterization of a rat mu opioid receptor.

Authors:  R C Thompson; A Mansour; H Akil; S J Watson
Journal:  Neuron       Date:  1993-11       Impact factor: 17.173

Review 4.  Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity.

Authors:  E Klann; E Thiels
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1999-04       Impact factor: 5.067

5.  Distinct domains of the mu-opioid receptor control uncoupling and internalization.

Authors:  Jeremy Celver; Mei Xu; Wenzhen Jin; Janet Lowe; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

6.  Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors.

Authors:  Duane A Chung; Susan M Wade; Carol B Fowler; Danielle D Woods; Paolo B Abada; Henry I Mosberg; Richard R Neubig
Journal:  Biochem Biophys Res Commun       Date:  2002-05-17       Impact factor: 3.575

7.  Transactivation joins multiple tracks to the ERK/MAPK cascade.

Authors:  Reinhard Wetzker; Frank-D Böhmer
Journal:  Nat Rev Mol Cell Biol       Date:  2003-08       Impact factor: 94.444

8.  Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes.

Authors:  L M Luttrell; S S Ferguson; Y Daaka; W E Miller; S Maudsley; G J Della Rocca; F Lin; H Kawakatsu; K Owada; D K Luttrell; M G Caron; R J Lefkowitz
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

9.  Mu opioid transactivation and down-regulation of the epidermal growth factor receptor in astrocytes: implications for mitogen-activated protein kinase signaling.

Authors:  Mariana M Belcheva; Yun Tan; Virginia M Heaton; Amy L Clark; Carmine J Coscia
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436

10.  Delta opioid activation of the mitogen-activated protein kinase cascade does not require transphosphorylation of receptor tyrosine kinases.

Authors:  H Kenneth Kramer; Irma Onoprishvili; Matthew L Andria; Kayane Hanna; Karina Sheinkman; Lisa B Haddad; Eric J Simon
Journal:  BMC Pharmacol       Date:  2002-03-01
View more
  17 in total

1.  Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling.

Authors:  Erica J Melief; Mayumi Miyatake; Michael R Bruchas; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-03       Impact factor: 11.205

2.  Signaling events initiated by kappa opioid receptor activation: quantification and immunocolocalization using phospho-selective KOR, p38 MAPK, and K(IR) 3.1 antibodies.

Authors:  Julia C Lemos; Clarisse A Roth; Charles Chavkin
Journal:  Methods Mol Biol       Date:  2011

Review 3.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

Review 4.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 5.  Epigenetics of µ-opioid receptors: intersection with HIV-1 infection of the central nervous system.

Authors:  Patrick M Regan; Rajnish S Dave; Prasun K Datta; Kamel Khalili
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

6.  Spinal Opioid Tolerance Depends upon Platelet-Derived Growth Factor Receptor-β Signaling, Not μ-Opioid Receptor Internalization.

Authors:  S Puig; K E Barker; S R Szott; P T Kann; J S Morris; H B Gutstein
Journal:  Mol Pharmacol       Date:  2020-07-28       Impact factor: 4.436

Review 7.  Molecular mechanisms of opioid receptor-dependent signaling and behavior.

Authors:  Ream Al-Hasani; Michael R Bruchas
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

8.  Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2.

Authors:  Jesse J Parry; Ronald Chen; Rebecca Andrews; Kimberly A Lears; Buck E Rogers
Journal:  Endocrinology       Date:  2012-04-11       Impact factor: 4.736

Review 9.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

Review 10.  Regulation and Functional Implications of Opioid Receptor Splicing in Opioid Pharmacology and HIV Pathogenesis.

Authors:  Patrick M Regan; Dianne Langford; Kamel Khalili
Journal:  J Cell Physiol       Date:  2015-11-24       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.